AES-350
CAS No. 847249-57-4
AES-350 ( —— )
产品货号. M24840 CAS No. 847249-57-4
AES-350 是一种有效的口服活性 HDAC6 抑制剂(IC50 和 Ki 分别为 0.0244 μM 和 0.035 μM)。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥2576 | 有现货 |
|
| 10MG | ¥4277 | 有现货 |
|
| 25MG | ¥7071 | 有现货 |
|
| 50MG | ¥9558 | 有现货 |
|
| 100MG | ¥13122 | 有现货 |
|
| 500MG | ¥26163 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AES-350
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AES-350 是一种有效的口服活性 HDAC6 抑制剂(IC50 和 Ki 分别为 0.0244 μM 和 0.035 μM)。
-
产品描述AES-350 is a potent and orally active HDAC6 inhibitor(IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively). It is also against HDAC-3, -8, and -11 in an enzymatic activity assay with IC50 values of 0.187 μM, 0.245 μM, and >1μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research.
-
体外实验In contrast, AES-350 has submicromolar activity (IC50=0.58±0.13 μM) against MV4-11 cells than to that of vorinostat (IC50=0.31±0.061 μM). AES-350 is more ligand efficient and exemplifies a large therapeutic index (IC50>30 μM in noncancerous MRC-9 cells). AES-350 is also shown to be effective in AML-3 (acute myeloid leukemia) cells (IC50=0.73 ± 0.12 μM).AES-350 (0.25-4 μM; 18 hours) induces MV4-11 cells apoptosis in a dose-dependent manner. The late apoptosis ratios are 8.74%, 11.7%,16.08%, 30.97%, and 38.48%, respectively at 0.25 μM-4 μM.An ELISA is performed using HeLa cervical cancer cell lysates, and HeLa cells highly express HDAC6 and are sensitive to AES-350. Correspondingly, ELISA assays depicted a dose-dependent increase in HDAC6 inhibition (IC50=0.58±0.13 μM), Western blot analysis shows that AES-350 (0.1-10 μM) induces a dose-dependent increase in acetylated α-tubulin (Ac-α-tubulin), a substrate of HDAC. Apoptosis Analysis Cell Line:MV4-11 cells Concentration:0.25 μM; 0.5 μM; 1.00 μM; 2.00 μM; 4.00 μM Incubation Time:18 hours Result:Revealed a clear dosedependent increase in the percentage of cells entering late-stage apoptosis, similar to SAHA.
-
体内实验AES-350 (oral gavage; 20 mg/kg; single dose) exhibits a relative good pharmacokinetic (PK) properties in CD-1 mice. The single dose oral bioavailability (F%) of 51 is 19.8%. In comparison, the reported F% for SAHA in mice is significantly lower (8%).
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点HDAC
-
受体HDAC11|HDAC3|HDAC6
-
研究领域——
-
适应症——
化学信息
-
CAS Number847249-57-4
-
分子量312.36
-
分子式C18H20N2O3
-
纯度>98% (HPLC)
-
溶解度DMSO:100 mg/mL (320.14 mM; Need ultrasonic)
-
SMILESCC(C)(C)C1=CC=C(C(NC2=CC=C(C(NO)=O)C=C2)=O)C=C1
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Andrew E Shouksmith, et al. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
产品手册
关联产品
-
Alteminostat
Alteminostat 是一种新型组蛋白脱乙酰酶 (HDAC) 抑制剂。
-
HDAC-IN-52
HDAC-IN-52 是一种含吡啶的 HDAC 抑制剂,抑制 HDAC1,HDAC2,HDAC3 和 HDAC10 的 IC50 分别为 0.189,0.227,0.440 和 0.446 μM。HDAC-IN-52 可用于癌症研究。
-
Remodelin Fluor
Remodelin Fluor 是 Remodelin 的小分子类似物,具有抗 NAT10 的体内活性。
021-51111890
购物车()
sales@molnova.cn

